|
- 9 New Treatments for Psoriatic Arthritis in Development
Researchers are studying several new treatments for psoriatic arthritis (PsA) in clinical trials, including sonelokimab, vunakizumab, and ivarmacitinib Many of these medications are designed as under-the-skin injections or oral pills
- Psoriatic arthritis: New drug Bimzelx shows promise as treatment
The drug company UCB recently developed a new PsA treatment called Bimzelx Bimzelx appears to be effective even in individuals who have not previously responded to treatment
- Newer Drug Treatments for Psoriatic Arthritis
Depending on its severity, psoriatic arthritis is typically treated with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate
- Novel and Emerging Therapies in Psoriatic Arthritis - RheumNow
Three innovative treatments: Zasocitinib, Vunakizumab, and Sonelokimab, as detailed in recent phase 2 trials, were presented at ACR 2024 Zasocitinib (TAK-279) is a selective oral TYK2 inhibitor and has shown robust efficacy in phase 2b trials
- JAK Inhibitors for Psoriatic Arthritis: How They Work, Side . . .
We still don't have a cure for psoriatic arthritis But biologic drugs and other new treatments like JAK inhibitors target the root causes of joint and skin symptoms New research is
- Innovative Treatments for Psoriatic Arthritis: What’s New in . . .
Over the years, advances in medical research have led to innovative treatments aimed at better managing the symptoms and progression of PsA Here’s a look at what’s new in the treatment landscape for psoriatic arthritis in 2024
- A New PsA Treatment Option - The National Psoriasis Foundation
BIMZELX ® is the first approved treatment for PsA, AS, and nr-axSpA that selectively inhibits both interleukin 17A and interleukin 17F, which are thought to be key proteins driving inflammation The FDA-recommended dosage for adults with active PsA is 160mg by subcutaneous injection every 4 weeks
|
|
|